Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

IGMS

IGM Biosciences Inc

Dec 11 • 04:00PM ET

9.25

Dollar change -0.24
Percentage change -2.53	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN VRTX BIIB REGN GILD INCY NBIX EXEL ALNY SRPT

| Held by: VTI VXF IWM DWAS IWO VTWO SCHA VHT IWC VTWG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.65	Insider Own	70.54%	Shs Outstand	34.06M	Perf Week	-6.57%
Market Cap	550.04M	Forward P/E	-	EPS next Y	-2.18	Insider Trans	-0.09%	Shs Float	17.52M	Perf Month	-28.18%
Income	-219.84M	PEG	-	EPS next Q	-0.74	Inst Own	30.82%	Short Float	15.43%	Perf Quarter	-18.79%
Sales	2.92M	P/S	188.37	EPS this Y	31.15%	Inst Trans	-5.81%	Short Ratio	8.71	Perf Half Y	14.48%
Book/sh	1.33	P/B	6.97	EPS next Y	32.63%	ROA	-56.45%	Short Interest	2.70M	Perf Year	49.19%
Cash/sh	3.68	P/C	2.51	EPS next 5Y	-	ROE	-132.11%	52W Range	5.58 - 22.50	Perf YTD	11.31%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-44.65%	ROI	-186.14%	52W High	-58.89%	Beta	0.01
Dividend TTM	-	Quick Ratio	5.22	Sales past 5Y	19.85%	Gross Margin	-206.37%	52W Low	65.77%	ATR (14)	1.20
Dividend Ex-Date	-	Current Ratio	5.22	EPS Y/Y TTM	26.89%	Oper. Margin	-7557.54%	RSI (14)	38.02	Volatility	8.97% 11.13%
Employees	224	Debt/Eq	0.58	Sales Y/Y TTM	57.64%	Profit Margin	-7534.03%	Recom	2.09	Target Price	20.60
Option/Short	Yes / Yes	LT Debt/Eq	0.50	EPS Q/Q	2.66%	Payout	-	Rel Volume	0.44	Prev Close	9.49
Sales Surprise	121.17%	EPS Surprise	-26.25%	Sales Q/Q	1.38%	Earnings	Nov 08 BMO	Avg Volume	310.35K	Price	9.25
SMA20	-5.74%	SMA50	-29.55%	SMA200	-13.94%	Trades		Volume	136,659	Change	-2.53%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-06-24	Initiated	BMO Capital Markets	Outperform	$21
Oct-01-24	Downgrade	Truist	Buy → Hold	$24 → $12
Oct-01-24	Downgrade	JP Morgan	Neutral → Underweight	$12 → $9
Feb-09-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$9 → $21
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral	$8
Dec-07-23	Downgrade	H.C. Wainwright	Buy → Neutral	$11 → $7
Nov-09-22	Resumed	Jefferies	Buy	$61 → $55
Oct-17-22	Initiated	JP Morgan	Neutral	$27
Aug-29-22	Initiated	BofA Securities	Buy	$34
Dec-13-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$51
Nov-05-21	Upgrade	Wedbush	Neutral → Outperform
Aug-26-21	Initiated	Morgan Stanley	Overweight	$100
Jan-29-21	Initiated	RBC Capital Mkts	Outperform	$121
Jan-19-21	Reiterated	H.C. Wainwright	Buy	$88 → $114
Dec-22-20	Downgrade	Wedbush	Outperform → Neutral
Jul-17-20	Initiated	Robert W. Baird	Outperform	$90
Jul-01-20	Initiated	H.C. Wainwright	Buy	$88
May-28-20	Initiated	SunTrust	Buy	$86
Apr-22-20	Initiated	Wedbush	Outperform	$73
Oct-14-19	Initiated	Stifel	Buy	$32

Show Previous Ratings

Nov-08-24 08:00AM	IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -9.32%
07:00AM	IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-24 07:00AM	IGM Biosciences to Present at Three Upcoming Investor Conferences (GlobeNewswire)
Oct-01-24 05:09PM	These Stocks Moved the Most Today: APA, Northrop, Boeing, Super Micro, HP Inc., Tesla, Li Auto, CVS, Ford, and More (Barrons.com) -12.33%
04:03PM	Top 1% Biotech, IGM Biosciences, Plummets On Scrapped Drug, C-Suite Makeover (Investor's Business Daily)
02:39PM	Loading…
02:39PM	These Stocks Are Moving the Most Today: APA, Northrop, Boeing, Super Micro, HP Inc., Tesla, Li Auto, CVS, Ford, and More (Barrons.com)
11:40AM	IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO (Benzinga)
09:52AM	IGM Biosciences Stock Drops Sharply on Pipeline Transformation to Autoimmune Diseases (Barrons.com)
08:00AM	IGM lays off staff in autoimmune pivot; Metsera ramps up obesity drug supply (BioPharma Dive)
Sep-30-24 04:01PM	IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity (GlobeNewswire)
Sep-18-24 09:33AM	IGM Biosciences (IGMS) Surges 11.6%: Is This an Indication of Further Gains? (Zacks) -5.83%
Sep-10-24 04:05PM	IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit (GlobeNewswire) +9.74%
Aug-22-24 12:00PM	All You Need to Know About IGM Biosciences (IGMS) Rating Upgrade to Buy (Zacks)
Aug-14-24 08:00AM	IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
09:35AM	Loading…
Jul-12-24 09:35AM	IGM Biosciences (IGMS) Soars 32.7%: Is Further Upside Left in the Stock? (Zacks)
May-29-24 07:00AM	IGM Biosciences to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-10-24 02:38PM	IGM Biosciences Inc (IGMS) Q1 2024 Earnings: Aligns with EPS Projections Amidst Clinical ... (GuruFocus.com) -7.71%
May-09-24 07:38AM	RBC Cuts Price Target on IGM Biosciences to $20 From $21, Keeps Outperform, Speculative Risk (MT Newswires) +8.35%
May-08-24 10:55PM	IGMS Stock Earnings: IGM Biosciences Meets EPS, Misses Revenue for Q1 2024 (InvestorPlace) -5.94%
05:55PM	IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:10PM	IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-07-24 07:00AM	IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference (GlobeNewswire)
May-03-24 10:00AM	IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) +6.79%
Apr-30-24 12:00PM	IGM Biosciences (IGMS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Apr-17-24 08:30AM	IGM Biosciences Announces Refocusing of Sanofi Collaboration (GlobeNewswire) -11.63%
Apr-10-24 07:00AM	IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum (GlobeNewswire) -6.41%
Mar-07-24 10:52PM	IGMS Stock Earnings: IGM Biosciences Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
05:45PM	IGM Biosciences, Inc. (IGMS) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:10PM	IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
09:55AM	Loading…
Mar-01-24 09:55AM	Wall Street Analysts Think IGM Biosciences, Inc. (IGMS) Could Surge 63.1%: Read This Before Placing a Bet (Zacks)
Feb-14-24 09:55AM	Wall Street Analysts Believe IGM Biosciences, Inc. (IGMS) Could Rally 35.08%: Here's is How to Trade (Zacks)
Feb-01-24 07:00AM	IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire) +8.17%
Jan-16-24 08:38AM	IGM Bio (IGMS) Stock Rallies 142% in 3 Months: Here's Why (Zacks) -12.89%
Jan-03-24 07:00AM	IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-08-23 04:09AM	15 Best Falling Stocks To Buy Now (Insider Monkey) -5.00%
Dec-06-23 02:44AM	Medivir to present at the Carlsquare Equity Research Investor Day (PR Newswire)
Dec-05-23 04:01PM	IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension (GlobeNewswire) +9.17%
Dec-01-23 05:32AM	Bulletin from Extraordinary General Meeting in Medivir AB (publ) (PR Newswire) -7.79%
Nov-27-23 03:52AM	Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC (PR Newswire)
Nov-22-23 02:46AM	Medivir to present at the Redeye Life Science Day (PR Newswire)
Nov-21-23 02:48AM	Medivir to present at the Erik Penser Bank Company Event (PR Newswire)
Nov-16-23 09:55AM	Does IGM Biosciences, Inc. (IGMS) Have the Potential to Rally 268.31% as Wall Street Analysts Expect? (Zacks)
Nov-14-23 07:28PM	IGM Biosciences Inc (IGMS) Reports Q3 2023 Financial Results and Pipeline Progress (GuruFocus.com) +21.90%
Nov-13-23 04:10PM	IGM Biosciences Announces Third Quarter 2023 Financial Results (GlobeNewswire)
03:49AM	Medivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC and shares positive response from Type D meeting with FDA (PR Newswire)
Nov-07-23 07:00AM	IGM Biosciences to Present at Two Upcoming Investor Conferences (GlobeNewswire) +10.43%
Oct-25-23 02:46AM	Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday (PR Newswire)
Oct-23-23 02:48AM	Nomination Committee of Medivir appointed (PR Newswire)
Oct-20-23 09:29AM	Change in Medivir's Board of Directors (PR Newswire)
Oct-05-23 07:29AM	Fostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cycles (PR Newswire) +7.26%
Oct-03-23 04:05PM	IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z. Thompson, Ph.D. to Board of Directors (GlobeNewswire) -7.06% -10.66%
Sep-20-23 04:36AM	Orchard Therapeutics PLC Sponsored ADR (ORTX) Soars 12.9%: Is Further Upside Left in the Stock? (Zacks)
Sep-06-23 07:00AM	IGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-10-23 08:59PM	Down More Than 50%: These 2 Strong Buy Stocks Are Too Cheap to Ignore (TipRanks)
Aug-03-23 05:25PM	IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:10PM	IGM Biosciences Announces Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-05-23 06:46AM	Daily Vickers Top Buyers & Sellers for 07/05/2023 (Argus Research)
Jul-03-23 04:01PM	IGM Announces Closing of Upsized Public Offering and Concurrent Private Placement and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Jun-30-23 09:48AM	While hedge funds own 27% of IGM Biosciences, Inc. (NASDAQ:IGMS), individual investors are its largest shareholders with 28% ownership (Simply Wall St.)
Jun-22-23 08:14PM	Strength Seen in IGM Biosciences, Inc. (IGMS): Can Its 7.6% Jump Turn into More Strength? (Zacks) +7.62%
07:58AM	IGM Announces Pricing of $107.3 Million Upsized Public Offering and Concurrent Private Placement (GlobeNewswire)
Jun-21-23 05:17PM	IGM Announces Proposed Public Offering and Concurrent Private Placement (GlobeNewswire) -5.50%
Jun-02-23 05:30PM	IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development (GlobeNewswire) +5.92% -22.13%
Jun-01-23 07:00AM	IGM Biosciences to Present at the Jefferies Healthcare Conference (GlobeNewswire) +6.56%
May-31-23 07:00AM	IGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis (GlobeNewswire)
May-30-23 07:00AM	IGM Biosciences to Host Conference Call and Webcast to Provide IGM-8444 Clinical Update (GlobeNewswire)
May-25-23 11:58AM	Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation (Simply Wall St.)
May-12-23 10:15AM	IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
09:05AM	IGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-02-23 07:00AM	IGM Biosciences to Present at Two Upcoming Investor Conferences (GlobeNewswire)
Apr-28-23 11:50AM	Bullish IGM Biosciences, Inc. (NASDAQ:IGMS) insiders filled their treasuries with US$1.6m worth of stock over last year (Simply Wall St.)
Apr-19-23 07:00AM	IGM Biosciences to Present at the Stifel 2023 Targeted Oncology Days (GlobeNewswire)
Apr-13-23 04:05PM	IGM Biosciences Announces Six Presentations at the American Society for Cancer Research Annual Meeting 2023 (GlobeNewswire) +14.63%
Apr-06-23 12:23PM	IGM Biosciences, Inc. (NASDAQ:IGMS) Q4 2022 Earnings Call Transcript (Insider Monkey)
Apr-01-23 09:17AM	Further weakness as IGM Biosciences (NASDAQ:IGMS) drops 11% this week, taking three-year losses to 77% (Simply Wall St.)
Mar-30-23 06:05PM	IGM Biosciences, Inc. (IGMS) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -19.27%
04:05PM	IGM Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-27-23 07:00AM	IGM Biosciences to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on March 30, 2023 (GlobeNewswire) +6.70%
Feb-02-23 07:00AM	IGM Biosciences to Present at the Guggenheim 2023 Oncology Conference (GlobeNewswire) +9.67%
Jan-17-23 07:00AM	IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-7354 in Solid Tumors (GlobeNewswire)
Jan-09-23 07:00AM	IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development (GlobeNewswire) +8.66%
Jan-03-23 07:00AM	IGM Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-22 10:00AM	IGM Biosciences Presents Data from T cell Engager Portfolio for Hematologic Malignancies at 2022 American Society of Hematology Annual Meeting (GlobeNewswire)
Dec-01-22 07:00AM	IGM Biosciences to Present at the Bank of America Biotech SMID Cap Conference (GlobeNewswire)
Nov-16-22 06:37AM	The Independent Director of IGM Biosciences, Inc. (NASDAQ:IGMS), M. Behrens, Just Bought 27% More Shares (Simply Wall St.)
Nov-08-22 07:00AM	IGM Biosciences to Present at Three Upcoming Investor Conferences (GlobeNewswire)
Nov-03-22 10:25AM	IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -8.46%
09:05AM	IGM Biosciences Announces Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-22 04:05PM	IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkins Lymphoma (GlobeNewswire)
Oct-27-22 02:06PM	Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation (Simply Wall St.)
Sep-06-22 07:00AM	IGM Biosciences to Present at Three Upcoming Investor Conferences (GlobeNewswire) -5.77%
Aug-08-22 06:45PM	IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +9.77% +11.31%
04:10PM	IGM Biosciences Announces Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-04-22 02:04PM	IGM Biosciences, Inc. (NASDAQ:IGMS) insiders placed bullish bets worth US$2.3m in the last 12 months (Simply Wall St.)
Jun-01-22 07:00AM	IGM Biosciences to Present at the 2022 Jefferies Healthcare Conference (GlobeNewswire)
May-20-22 12:07PM	We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate (Simply Wall St.)
May-10-22 07:00AM	IGM Biosciences to Present at the 2022 RBC Capital Markets Global Healthcare Conference (GlobeNewswire) +5.34%
May-09-22 04:16PM	IGM Biosciences Announces First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -12.23%
May-06-22 07:00AM	IGM Biosciences Announces Closing of Global Collaboration Agreement with Sanofi (GlobeNewswire)

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm's product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Weber Steven	PRINCIPAL ACCOUNTING OFFICER	Sep 13 '24	Sale	11.54	469	5,412	25,543	Sep 17 08:58 PM
Takimoto Chris H	CHIEF MEDICAL OFFICER	Sep 13 '24	Sale	11.54	1,487	17,158	154,331	Sep 17 08:55 PM
Tahir Misbah	CHIEF FINANCIAL OFFICER	Sep 13 '24	Sale	11.54	1,487	17,158	122,694	Sep 17 08:54 PM
Schwarzer Fred	CEO AND PRESIDENT	Sep 13 '24	Sale	11.54	3,946	45,532	250,124	Sep 17 08:52 PM
Keyt Bruce	CHIEF SCIENTIFIC OFFICER	Sep 13 '24	Sale	11.54	1,487	17,158	242,948	Sep 17 08:50 PM
Harler Mary Beth	Head, Research & Autoimmunity	Sep 13 '24	Sale	11.54	1,487	17,158	163,740	Sep 17 08:44 PM
Decker Lisa Lynn	CHIEF BUSINESS OFFICER	Sep 13 '24	Sale	11.54	925	10,673	79,104	Sep 17 08:42 PM
Hambleton Julie	Director	Jul 25 '24	Option Exercise	1.39	15,132	21,033	17,132	Jul 29 05:45 PM
Hambleton Julie	Director	Jul 25 '24	Sale	14.00	15,132	211,848	2,000	Jul 29 05:45 PM
Weber Steven	PRINCIPAL ACCOUNTING OFFICER	Jun 14 '24	Sale	7.58	495	3,750	26,012	Jun 18 07:45 PM
Takimoto Chris H	CHIEF MEDICAL OFFICER	Jun 14 '24	Sale	7.58	1,570	11,893	95,818	Jun 18 07:44 PM
Tahir Misbah	CHIEF FINANCIAL OFFICER	Jun 14 '24	Sale	7.58	1,570	11,893	88,848	Jun 18 07:43 PM
Schwarzer Fred	CEO AND PRESIDENT	Jun 14 '24	Sale	7.58	4,164	31,544	254,070	Jun 18 07:42 PM
Keyt Bruce	CHIEF SCIENTIFIC OFFICER	Jun 14 '24	Sale	7.58	1,106	8,378	197,769	Jun 18 07:41 PM
Harler Mary Beth	Head, Research & Autoimmunity	Jun 14 '24	Sale	7.58	1,570	11,893	85,227	Jun 18 07:40 PM
Decker Lisa Lynn	CHIEF BUSINESS OFFICER	Jun 14 '24	Sale	7.58	977	7,401	60,029	Jun 18 07:38 PM
BAKER BROS. ADVISORS LP	Director	Mar 26 '24	Buy	8.26	270,000	2,230,767	3,638,533	Mar 28 07:04 PM
BAKER BROS. ADVISORS LP	Director	Mar 28 '24	Buy	9.62	97,473	937,632	3,753,480	Mar 28 07:04 PM
BAKER BROS. ADVISORS LP	Director	Mar 27 '24	Buy	9.24	27,844	257,170	3,664,073	Mar 28 07:04 PM
Weber Steven	PRINCIPAL ACCOUNTING OFFICER	Mar 13 '24	Sale	9.88	529	5,224	26,971	Mar 15 07:57 PM
Weber Steven	PRINCIPAL ACCOUNTING OFFICER	Mar 14 '24	Sale	10.17	464	4,719	26,507	Mar 15 07:57 PM
Takimoto Chris H	CHIEF MEDICAL OFFICER	Mar 13 '24	Sale	9.88	2,889	28,529	96,923	Mar 15 07:55 PM
Takimoto Chris H	CHIEF MEDICAL OFFICER	Mar 14 '24	Sale	10.17	2,535	25,782	94,388	Mar 15 07:55 PM
Tahir Misbah	CHIEF FINANCIAL OFFICER	Mar 13 '24	Sale	9.88	2,897	28,608	92,961	Mar 15 07:53 PM
Tahir Misbah	CHIEF FINANCIAL OFFICER	Mar 14 '24	Sale	10.17	2,543	25,864	90,418	Mar 15 07:53 PM
Schwarzer Fred	CEO AND PRESIDENT	Mar 13 '24	Sale	9.88	4,765	47,055	220,833	Mar 15 07:51 PM
Schwarzer Fred	CEO AND PRESIDENT	Mar 14 '24	Sale	10.17	4,182	42,533	216,651	Mar 15 07:51 PM
Keyt Bruce	CHIEF SCIENTIFIC OFFICER	Mar 13 '24	Sale	9.88	2,101	20,748	173,700	Mar 15 07:49 PM
Keyt Bruce	CHIEF SCIENTIFIC OFFICER	Mar 14 '24	Sale	10.17	1,844	18,754	171,856	Mar 15 07:49 PM
Decker Lisa Lynn	CHIEF BUSINESS OFFICER	Mar 13 '24	Sale	9.88	1,798	17,756	62,584	Mar 15 07:48 PM
Decker Lisa Lynn	CHIEF BUSINESS OFFICER	Mar 14 '24	Sale	10.17	1,578	16,049	61,006	Mar 15 07:48 PM
Keyt Bruce	CHIEF SCIENTIFIC OFFICER	Mar 01 '24	Option Exercise	0.93	3,026	2,814	4,039	Mar 05 07:34 PM
Schwarzer Fred	CEO and President	Dec 13 '23	Sale	5.78	17,576	101,558	102,848	Dec 15 07:20 PM
Keyt Bruce	Chief Scientific Officer	Dec 13 '23	Sale	5.78	7,574	43,764	129,551	Dec 15 07:19 PM
Decker Lisa Lynn	Chief Business Officer	Dec 13 '23	Sale	5.78	4,369	25,245	35,632	Dec 15 07:18 PM
BAKER BROS. ADVISORS LP	Director	Dec 15 '23	Buy	6.55	288,007	1,887,531	3,390,323	Dec 15 05:32 PM
BAKER BROS. ADVISORS LP	Director	Dec 14 '23	Buy	6.50	157,370	1,023,157	3,123,585	Dec 15 05:32 PM
BAKER BROS. ADVISORS LP	Director	Dec 13 '23	Buy	5.96	87,316	520,776	2,977,836	Dec 15 05:32 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IGMS

IGM Biosciences Inc

Upgrade your FINVIZ experience